Clinical trials: Open Access
Neuroblastoma, Pheochromocytoma
Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Currently there is no known effective treatment for patients with advanced stage neuroblastoma who have relapsed or not responded to standard therapy.
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT01838187
- Testing
- I-131 MIBG, Vorinostat
- Where
- United States
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Chronic Lymphocytic Leukemia
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
This is a multicenter, open-label, single-arm, expanded access treatment study designed to provide obinutuzumab to patients with previously untreated Chronic Lymphocytic Leukemia (CLL) in combination with chlorambucil and to…
- Trial name
- NCT01868893
- Testing
- Obinutuzumab, Chlorambucil
- Where
- 19 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors, Cholangiocarcinoma
Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors
This study is an open-label, multicenter study for Continued Characterization of Safety and Tolerability of TT-00420 (tinengotinib) Tablet Monotherapy in Adult Patients with Advanced Solid Tumors
- Trial name
- NCT06370013
- Testing
- Tinengotinib
- Where
- 5 sites in United States
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Central Line, Central Venous Catheter
Statseal® for Central Venous Catheter Insertion Sites in Critical Care
All participants in this clinical trial will be undergoing surgery and will have a central venous catheter (also known as a central line) placed in the large vein in the neck as part of their routine care.
- Conditions
- Central Line, Central Venous Catheter, Vascular Access, Critical Care
- Trial name
- SCENIC (NCT06451185)
- Testing
- A haemostatic mineral powder product.
- Where
- United Kingdom
- Volunteers
- 451 people
- Sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
HIV Infections
An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.
To provide an alternative therapy to HIV-infected patients for whom there is no comparable or satisfactory alternative drug or therapy available.
- Trial name
- NCT00002173
- Testing
- HIV-1 Immunogen
- Where
- United States
- Sponsor
- The Immune Response Corporation
Esophageal Diseases, Peptic Ulcer
Drop in Gastroscopy - Experience After 9 Months
The capacity for endoscopical procedures in the Norwegian health system is low in comparison to demands from patients and family practitioners.
- Conditions
- Esophageal Diseases, Peptic Ulcer, Stomach Diseases
- Trial name
- NCT00977678
- Testing
- open access gastroscopy, Gastroscopy by appointment
- Where
- Norway
- Volunteers
- 213 people
- Sponsor
- Norwegian Department of Health and Social Affairs
Chronic Hepatitis B
Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States
The objective of this study is to provide open label emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for an additional 5 years (240 weeks) to adults completing study GS-US-203-0107.
- Trial name
- NCT00936715
- Testing
- FTC/TDF
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Arteriovenous Fistula Renal Dialysis Devices Obstruction
Primary Patency in Post-angioplasty Dysfunctional Arteriovenous Fistula in Renal Dialysis: Paclitaxel-releasing PTA Balloon Catheter vs PTA Balloon
In recent years the use of paclitaxel releasing percutaneous transluminal angioplastic (PTA) balloon catheter is spreading in vascular pathology, mainly in stenosis infrainguinal arteries.
- Trial name
- FISBAL (NCT02565953)
- Testing
- Paclitaxel-releasing PTA balloon catheter, PTA balloon catheter
- Where
- 4 sites in Spain
- Volunteers
- 134 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Mucopolysaccharidosis IVA, Morquio A Syndrome
BMN 110 US Expanded Access Program
The Expanded Access Program (EAP) is an open-label, multicenter program to: 1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available 2.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01858103
- Testing
- BMN 110
- Where
- 25 sites in United States, Puerto Rico
- Sponsor
- BioMarin Pharmaceutical
Type 2 Diabetes Mellitus
A Clinical Study to Access the Pharmacokinetics of HMS5552 in Renal Impaired Subjects and Healthy Volunteers
The objectives of this study is to access the pharmacokinetics and safety of HMS5552 in single dose in renal impaired subjects and matched healthy adult subjects.
- Trial name
- NCT04324424
- Testing
- HMS5552
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hua Medicine Limited
Hepatitis C
Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
The purpose of this early access program is to provide telaprevir to patients with a specific type of hepatitis C viral infection (termed 'genotype 1') who are expected to benefit from telaprevir-based therapy but who reside in…
- Trial name
- NCT01508286
- Testing
- Telaprevir + peginterferon alfa + ribavirin, peginterferon alfa + ribavirin
- Where
- 128 sites in Australia, Austria and 13 more
- Sponsor
- Janssen-Cilag International NV
Limb Ischemia
Combined Management in ALI ( Image Guided Thrombectomy With Open Transfemoral Access )
Acute limb ischemia (ALI) is a sudden decrease in limb perfusion due to either an embolic or a thrombotic vascular occlusion, defined as the presence of symptoms within two weeks of onset.
- Trial name
- NCT04622878
- Testing
- thrombectomy and PTA
- Volunteers
- 100 people
- Sponsor
- Assiut University